Long-term follow up of carbohydrate metabolism and adverse events after termination of Omnitrope® treatment in children born small for gestational age.

"Conflict of interest statement: MS has been involved in clinical trials for, and received consultancy and speaker’s fees from, Novo Nordisk, Pfizer, AstraZeneca, and Sandoz.: MW has received fees from Sandoz as the country coordinating investigator for the study in Poland.: JL has been involved in clinical trials for, and received consultancy and speaker’s fees from, Pfizer, Novo Nordisk, Merck, and Sandoz.: FM, MN, GH and BKF have no relevant financial or non-financial interests to disclose.: TG and HZ are employees of Sandoz Biopharmaceuticals."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: the EP00-402 study was funded by Sandoz Biopharmaceuticals, c/o HEXAL AG."